Compare PDSB & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | SACH |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5M | 52.0M |
| IPO Year | N/A | 2017 |
| Metric | PDSB | SACH |
|---|---|---|
| Price | $0.88 | $1.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.00 | $2.00 |
| AVG Volume (30 Days) | ★ 592.3K | 265.9K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 20.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,906,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $0.80 |
| 52 Week High | $2.20 | $1.40 |
| Indicator | PDSB | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 41.27 |
| Support Level | $0.86 | $0.99 |
| Resistance Level | $0.93 | $1.05 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.26 | 3.04 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.